SpineThera Inc is a pharmaceutical firm developing sustained-release, injectable drugs to meet the unique safety requirements for administration in and near the spine. The firm's lead drug product candidate utilizes patent protected sustained-release drug-delivery technology is designed to meet the specific and unique needs of epidural administration and back pain. The firm's technology has the potential significantly to extend the duration of back pain relief from a single epidural injection compared to the generic steroids which are routinely used off-label today. The active ingredient the firm's lead drug candidate is a synthetic adrenal corticosteroid with potent anti-inflammatory properties and that has been reformulated using SpineThera's sustained-release drug-delivery platform - encapsulating the ingredient into an injectable micro-suspension containing tiny biodegradable microspheres designed for epidural administration to provide opioid-free relief from lower-back pain for 60-90 days.Though having a limited SBIR presence, the firm was in receipt of a $2M award from US Army in 2017
